Stockscreener 앱 받기
6.01
6.37%
0.36
전일 마감가:
$5.65
열려 있는:
$5.64
하루 거래량:
464.61K
Relative Volume:
1.13
시가총액:
$129.16M
수익:
-
순이익/손실:
$-30.54M
주가수익비율:
-3.8774
EPS:
-1.55
순현금흐름:
$-18.30M
1주 성능:
+4.16%
1개월 성능:
-3.53%
6개월 성능:
+28.14%
1년 성능:
+672.69%
1일 변동 폭
$5.62
$6.06
1주일 범위
$5.36
$6.06
52주 변동 폭
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
UNCY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.01 | 121.43M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | Guggenheim | Buy |
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Unicycive Therapeutics : January 2026 Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - MarketScreener
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - MarketScreener
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum ... - Caledonian Record
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - MarketScreener
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Yahoo Finance
Rally Mode: Can Unicycive Therapeutics Inc stock continue upward trendJuly 2025 Outlook & Fast Moving Stock Trade Plans - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Why Unicycive Therapeutics Inc. stock is a must watch in 2025Trade Risk Summary & Verified Stock Trade Ideas - Улправда
Is Unicycive Therapeutics Inc. stock a top momentum playLong Setup & Smart Investment Allocation Insights - Улправда
Will Unicycive Therapeutics Inc. stock remain a Wall Street favorite2025 Biggest Moves & Long-Term Growth Stock Strategies - Bollywood Helpline
How Unicycive Therapeutics Inc. stock performs after earningsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
How Unicycive Therapeutics Inc. stock benefits from tech adoptionLong Setup & Daily Technical Forecast Reports - Улправда
Will Unicycive Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Summary & Long-Term Growth Plans - Bölüm Sonu Canavarı
Can Unicycive Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Weekly Recap & Consistent Profit Alerts - Улправда
Why analysts upgrade Unicycive Therapeutics Inc. stockEarnings Performance Report & Fast Exit Strategy with Risk Control - DonanımHaber
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025Portfolio Performance Report & Accurate Entry and Exit Point Alerts - DonanımHaber
Can Unicycive Therapeutics Inc. stock continue upward trend2025 Stock Rankings & Daily Profit Focused Stock Screening - DonanımHaber
How interest rate cuts could boost Unicycive Therapeutics Inc. stockWeekly Investment Report & Free Fast Gain Swing Trade Alerts - DonanımHaber
How geopolitical tensions affect Unicycive Therapeutics Inc. stockJuly 2025 Fed Impact & High Accuracy Swing Trade Signals - ulpravda.ru
Aug Summary: Why Unicycive Therapeutics Inc. stock is a must watch in 20252025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chart Watch: Why analysts upgrade Unicycive Therapeutics Inc stock2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Unicycive is all-in on kidney care, focusing on underserved areas: CEO - AlphaStreet
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6%Time to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Important Notice to Long-Term Shareholders of Five Below, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):